Integrated Biopharma Stock Current Valuation
| INBPDelisted Stock | USD 0.23 0.01 4.55% |
Valuation analysis of Integrated Biopharma helps investors to measure Integrated Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Integrated Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Integrated Biopharma is based on 3 months time horizon. Increasing Integrated Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Integrated Biopharma is useful when determining the fair value of the Integrated otc stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Integrated Biopharma. Since Integrated Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Integrated OTC Stock. However, Integrated Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.23 | Real 0.21 | Hype 0.26 | Naive 0.22 |
The real value of Integrated OTC Stock, also known as its intrinsic value, is the underlying worth of Integrated Biopharma OTC Stock, which is reflected in its stock price. It is based on Integrated Biopharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Integrated Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integrated Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Integrated Biopharma helps investors to forecast how Integrated otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integrated Biopharma more accurately as focusing exclusively on Integrated Biopharma's fundamentals will not take into account other important factors: Integrated Biopharma OTC Stock Current Valuation Analysis
Integrated Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Integrated Biopharma Current Valuation | 12.05 M |
Most of Integrated Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Integrated Biopharma has a Current Valuation of 12.05 M. This is 99.94% lower than that of the Personal Products sector and 99.88% lower than that of the Consumer Staples industry. The current valuation for all United States stocks is 99.93% higher than that of the company.
Integrated Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.Integrated Biopharma is currently under evaluation in current valuation category among related companies.
Integrated Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 12.05 M | ||||
| Shares Outstanding | 29.95 M | ||||
| Shares Owned By Insiders | 68.58 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Price To Earning | 2.52 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 56.25 M | ||||
| Gross Profit | 6.55 M | ||||
| EBITDA | 3.54 M | ||||
| Net Income | 3.84 M | ||||
| Cash And Equivalents | 343 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 53 K | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | 4.09 M | ||||
| Earnings Per Share | 0.11 X | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 11.2 M | ||||
| Total Asset | 25.25 M | ||||
| Retained Earnings | (59.89 M) | ||||
| Working Capital | 913 K | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 11.79 M | ||||
| Net Asset | 25.25 M |
About Integrated Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integrated Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Integrated Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Integrated Biopharma's short interest history, or implied volatility extrapolated from Integrated Biopharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |